Publication: Efficacy of dexamethasone implants in uveitic macular edema in cases with behcet disease
dc.contributor.author | Yalçınbayır, Özgür | |
dc.contributor.author | Çalışkan, Enver | |
dc.contributor.author | Gündüz, Gamze Uçan | |
dc.contributor.author | Gelişken, Öner | |
dc.contributor.author | Kaderli, Berkant | |
dc.contributor.author | Yücel, Ahmet Ali | |
dc.contributor.buuauthor | YALÇINBAYIR, ÖZGÜR | |
dc.contributor.buuauthor | Çalışkan, Enver | |
dc.contributor.buuauthor | UÇAN GÜNDÜZ, GAMZE | |
dc.contributor.buuauthor | YÜCEL, AHMET ALİ | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göz Hastalıkları Anabilim Dalı | |
dc.contributor.researcherid | JAC-9459-2023 | |
dc.contributor.researcherid | EQX-5743-2022 | |
dc.contributor.researcherid | AAH-6661-2021 | |
dc.contributor.researcherid | JYV-1141-2024 | |
dc.date.accessioned | 2024-07-18T08:19:53Z | |
dc.date.available | 2024-07-18T08:19:53Z | |
dc.date.issued | 2019-01-01 | |
dc.description.abstract | Purpose: Investigation of the efficacy of intravitreal dexamethasone implants (0.7 mg) in patients with Behcet disease (BD) who had cystoid macular edema (CME) despite immunomodulatory treatment. Materials and Methods: Twenty-seven eyes of 20 patients who had intravitreal dexamethasone implant injections and follow-up for more than 6 months were included in this study. Best corrected visual acuities (BCVA), intraocular pressures (IOP), and central macular thicknesses (CMT) were recorded. Systemic immunomodulatory treatment was noted. Injection-related complications and the need for recurrent injections were recorded. Results: Statistically significant anatomical and functional success was achieved with a single injection. BCVA increased from 0.85 +/- 0.72 to 0.45 +/- 0.52 logMAR, while the mean CMT decreased from 406 +/- 190 to 243 +/- 101 mu m at the sixth month. The peak of visual acuity gain was reached within the first 2 months and a substantial proportion of the patients gained 3 or more lines. There was no complication other than transient IOP elevation in 4 eyes and cataract surgery in 2 eyes. Conclusion: Adjuvant intravitreal dexamethasone implant injections offer promising results in cases of BD with CME. It is effective in preserving the macular anatomy and vision particularly in transition to biological agents. | |
dc.identifier.doi | 10.1159/000490674 | |
dc.identifier.eissn | 1423-0267 | |
dc.identifier.endpage | 194 | |
dc.identifier.issn | 0030-3755 | |
dc.identifier.issue | 4 | |
dc.identifier.startpage | 190 | |
dc.identifier.uri | https://doi.org/10.1159/000490674 | |
dc.identifier.uri | https://karger.com/oph/article/241/4/190/264076/Efficacy-of-Dexamethasone-Implants-in-Uveitic | |
dc.identifier.uri | https://hdl.handle.net/11452/43334 | |
dc.identifier.volume | 241 | |
dc.identifier.wos | 000466138500003 | |
dc.indexed.wos | WOS.SCI | |
dc.language.iso | en | |
dc.publisher | Karger | |
dc.relation.journal | Ophthalmologica | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | Intravitreal implant | |
dc.subject | Posterior uveitis | |
dc.subject | Risk | |
dc.subject | Outcomes | |
dc.subject | Therapy | |
dc.subject | Adjuvant | |
dc.subject | Dexamethasone implant | |
dc.subject | Cystoid macular edema | |
dc.subject | Uveitis | |
dc.subject | Science & technology | |
dc.subject | Life sciences & biomedicine | |
dc.subject | Ophthalmology | |
dc.title | Efficacy of dexamethasone implants in uveitic macular edema in cases with behcet disease | |
dc.type | Article | |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | e21cc14e-0a29-42c8-a7a0-93bd3c780b36 | |
relation.isAuthorOfPublication | fcd16549-6bb4-4c75-9919-689a032002f2 | |
relation.isAuthorOfPublication | 34be4f44-59fb-4838-9179-a4b19b9575e6 | |
relation.isAuthorOfPublication.latestForDiscovery | e21cc14e-0a29-42c8-a7a0-93bd3c780b36 |